ImmuCell Corporation — Balance Sheet (NASDAQ:ICCC) | MetaTrader

Open full chart

Financials

Overview 声明 Statistics Dividends

Quarterly Annual

Total assets 40.35 M44.47 M44.86 M43.81 M45.1 M Total liabilities 12.08 M11.89 M14.48 M18.82 M17.58 M Total equity 28.27 M32.58 M30.38 M24.99 M27.52 M Total liabilities & shareholders' equities 40.35 M44.47 M44.86 M43.81 M45.1 M Total debt ———22.33 M— Net debt ———21.35 M—

新闻

ImmuCell董事将在2026年年度股东大会上卸任，董事会预计将发生变动

ImmuCell directors to step down at 2026 annual meeting, board changes expected

ImmuCell宣布新高管雇佣协议及期权授予

ImmuCell announces new executive employment agreements and option grants

Niche Focus & Regulation Shape the Future of Healthcare Firms

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

盈利电话会议记录：ImmuCell 2025年第四季度股价走势向好

Earnings call transcript: ImmuCell Q4 2025 sees positive stock movement

ImmuCell公司报告第四季度销售额为760万美元，将重心转向First Defense

ImmuCell reports Q4 sales of $7.6 million, shifts focus to First Defense

ImmuCell Puts Re-Tain On Pause After FDA Letter - ImmuCell (NASDAQ:ICCC)

The Zacks Analyst Blog AbbVie, The Coca-Cola, Chevron, ImmuCell and Precipio